ApoCIII-Lp(a) Complexes With Lp(a)-OxPL Predict Rapid Progression of Aortic Stenosis

Building on earlier work tying lipoprotein(a) to faster valve disease, this study added another molecular player — apolipoprotein C-III — to the picture, refining who progresses most quickly.

In 218 patients with mild-to-moderate aortic stenosis, the investigators measured complexes of apoC-III bound to Lp(a), alongside Lp(a)-associated oxidized phospholipids. Patients with high levels of both — particularly in the top tertile — progressed faster and had higher rates of valve replacement or cardiac death. ApoC-III turned out to be present both on circulating Lp(a) and within the diseased valve tissue itself, suggesting it participates in the inflammatory, calcifying process rather than merely marking it.

The work deepens the mechanistic story and points toward a more granular risk stratification: not just “high Lp(a),” but the specific molecular companions that make a given person’s Lp(a) more dangerous to the valve.

We rate the evidence moderate-to-strong. It is a sound prospective study with detailed molecular analysis, though its specialized biomarkers remain research tools rather than clinical tests.